Robbins LLP Urges RARE Stockholders to Contact the Firm for Information About the Class Action Against Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: GlobeNewswire
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025. Ultragenyx is a biopharmaceutical company focused on rare and ultrarare genetic disorders. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? Robbins LLP is Investigating Allegations that Ultragenyx Pharmaceutical Inc. (RARE) Misled Investors Regarding Phase III Orbit and Cosmic Studies for Setrusumab According to the complaint, during the class period, defendants provided investors with material information concerning Ultragenyx’s expected results for its Phase III Orbit and Cosmic Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta (“OI”). Defendants’ statements included, among other things, c
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RAREGlobeNewswire
- Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD LawPR Newswire
- Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
- UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action – April 6, 2026 Lead Plaintiff Deadline - Furuqi & Furuqi LLPGlobeNewswire
- LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSUREPR Newswire
RARE
Earnings
- 2/12/26 - Miss
RARE
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- RARE's page on the SEC website